Screener
Sionna Therapeutics SION Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Sionna Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Sionna Therapeutics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 7:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033876
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Payment of deferred offering costs | (320) | — |
| Exercise of common stock options | 2,213 | — |
| Net cash provided by financing activities | 1,893 | 202,389 |
| Net increase in cash, cash equivalents and restricted cash | 4,873 | 44,907 |
| Cash, cash equivalents and restricted cash at beginning of period | 59,414 | 38,750 |
| Cash, cash equivalents and restricted cash at end of period | $64,287 | $83,657 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Conversion of convertible preferred stock into common stock upon closing of initial public offering | — | $330,368 |
Item 1. Financial Statements
FAQ
- What is Sionna Therapeutics's net change in cash?
- Sionna Therapeutics (SION) reported net change in cash of $4.87M in Q1 2026.
- How has Sionna Therapeutics's net change in cash changed year-over-year?
- Sionna Therapeutics's net change in cash decreased by 89.1% year-over-year, from $44.91M to $4.87M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Sionna Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude